Bio pharmazeutika werden would be the latest era of drugs which can be produced by using living cell material. They are simply used to treat a large variety of ailments and conditions. Manufacturing them is known as a sophisticated process that requires a team of fully commited professionals to complete.

As opposed to small molecule-based medicines, which can be created using classic chemistry methods, Biopharmazeutika are incredibly complex and have to become produced in living organisms, such as bacteria (e. g. rekombinante Escherichia coli oder Hefekulturen), mammalian cells (e. g. CHO-Zellen) or perhaps plants that are made through gene technology (Pflanzenbiotechnologie). They are consequently processed in bioreactors to generate the desired medicine.

Once the desired biopharmazeutika can be produced, it can be attached to a polymer including the popular thready Monomethoxypolyethylenglycol-Ketten, commonly known as PEGs, which can be then used for various applications, which include drug delivery systems. This enables the biopharmazeutika being more easily transferred into focus on organs and also to exert their effects.

A biopharmazeutika-PEG conjugate consists of a PEG molecule and a peptide using a linker, which can be usually a thiol group, a carboxylic acid or an protide. This enables the linker to attach to different biological molecules, such as peptides and antibodies. This permits the biopharmazeutika-PEG-conjugate to be guaranteed to biologically productive molecules in order to deliver them into the body, where they may be taken up by immune system and after that used to deal with index disease. This method is also being used to generate vaccines, which will then be used in order to support fight diseases such as rheumatoid arthritis and multiple sclerosis.